Keylika Inc

Keylika is a biotechnology startup that focuses on drug discovery and delivery, specifically developing metallodrugs for unmet medical needs. The company has created a proprietary platform synthesis technology to produce new mixed ligand iron molecules. Its primary innovation is NistuFe, a novel small molecule iron drug designed for transdermal delivery via a wearable skin patch. By allowing the iron to be absorbed through the skin directly into the systemic circulation, the patch bypasses the gastrointestinal tract, aiming to provide a safer and more convenient alternative to oral supplements and IV iron infusions without associated side effects like nausea or the need for clinical hospitalization.

This technology is intended to significantly improve clinical outcomes, safety, and patient tolerability for the estimated 1.6 billion people worldwide affected by iron deficiency anemia. By enabling self-administration at home, Keylika seeks to redefine the standard of care for iron deficiency. Founded in 2022 and based in Walnut Creek, California, the company was part of the Y Combinator Summer 2022 cohort. Beyond hematology, Keylika is positioned to leverage its synthesis platform to address other therapeutic areas, including metabolic disorders, pain, inflammation, infectious diseases, and oncology.